SUN PHARMACEUTICAL INDUSTRIES
Article Abstract:
The net profit of Sun Pharmaceutical Industries (SPIL) increased by 12.2 percent to Rs561.20 million for 1997-98. It has set up units at Panoli, Silvassa and Vapi. A research and development centre, Sun Pharma Advanced Research Centre has been set up at Baroda. SPIL has acquired a bulk drug plant at Ahmednagar from Knoll Pharma. It has acquired the pharmaceutical firm, Caraco of the US. It has controlling stake in MJ Pharma and Gujarat Lyka. Tamilnadu Dadha Pharmaceuticals was merged with SPIL with effect from April 1, 1997. SPIL manufactures formulations for psychiatry, cardiac care and central nervous system. In 1997-98, its sales increased by 8.2 percent and exports increased by 86.8 percent. (rk) ------------------------------------------------------------ Financial Performance of Sun Pharmaceutical Industries Ltd (Rs in million) ------------------------------------------------------------ Particulars 1997-98 ------------------------------------------------------------ Sales 2,675.80 ------------------------------------------------------------ Gross profit 631.00 ------------------------------------------------------------ Net profit 561.20 ------------------------------------------------------------ Equity 152.10 ------------------------------------------------------------ Earnings per share (Rs) 36.90 ------------------------------------------------------------ Market price of share (Rs) 365.50 ------------------------------------------------------------
Comment:
Registers 12.2% increase in net profit to Rs561.20 mil on sales of Rs2,675.80 mil for 1997-98
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
KOPRAN LTD
Article Abstract:
Kopran Ltd posted a net profit of Rs61.40 million for 6 months ended September 1997. It focuses on semi-synthetic, Pencillin-G based antibiotic bulk drugs such as Amoxycillin, and Ampicillin. Its major brands include Aten, Vent, Tini Trasic, Soloflox and Zimat. It has launched herbal oral care products under Smyle brand. It launched a cough syrup and a product for treating mouth ulcers in the second half of 1997-98. (rk) ------------------------------------------------------------ Financial Performance of Kopran Ltd (Rs in million) ------------------------------------------------------------ Particulars 1996-97 1H 1997-98 ------------------------------------------------------------ Sales 3,438.00 1,406.20 ------------------------------------------------------------ Gross profit 672.30 227.20 ------------------------------------------------------------ Net profit 392.90 61.40 ------------------------------------------------------------ Equity 143.00 143.00 ------------------------------------------------------------ Earnings per share (Rs) 27.50 8.60 ------------------------------------------------------------ Market price of share (Rs) 127.50 127.50 ------------------------------------------------------------
Comment:
Launches a cough syrup and a product for treating mouth ulcers in the second half of 1997-98
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
DR REDDY's LABORATORIES
Article Abstract:
Dr Reddy's Laboratories (DRL) recorded a 32.7 percent increase in sales in 1997-98. Exports account for 33 percent of its sales. Its net profit increased by 45.7 percent. Its turnover is likely to increase by 25 percent per annum in the next few years. Sales of formulations is expected to increase by 70 percent in 1998-99 (62 percent in 1996-97). DRL focuses on formulations particularly anti-ulcer, cardiac care and antibiotics. Its main brands include Sporidex, Cifran and Roscillin in the anti-biotic segment. (rk) ------------------------------------------------------------ Performance of Dr. Reddy's Laboratories (Rs in million) ------------------------------------------------------------ Particulars 1997-98 ------------------------------------------------------------ Sales 3,316.2 ------------------------------------------------------------ Gross profit 710.5 ------------------------------------------------------------ Net profit 488.5 ------------------------------------------------------------ Equity 264.9 ------------------------------------------------------------ Earnings per share (Rs) 18.4 ------------------------------------------------------------ Market price of share (Rs) 471.5 ------------------------------------------------------------
Comment:
Records a 32.7% increase in sales to Rs3,316.2 mil in 1997-98
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: SMITHKLINE BEECHAM PHARMACEUTICALS (INDIA) LOSING ITS CAHRGE
- Abstracts: LIC HOUSING FINANCE LIMITED THE INDUSTRIAL FINANCE CORPORATION OF INDIA LTD 2 FINANCE Cos MAKE OPEN OFFER FOR DELTA PAPER MILLS
- Abstracts: SANGAMESHWAR COFFEE ESTATES AND INDUSTRIES LIMITED THE RAJENDRA COFFEES LIMITED. COFFEE BOARD TO INVITE FOREIGN ROASTERS TO INDIA
- Abstracts: LUPIN LABORATORIES LTD CIPLA TURBULENT TIMES